Industry Responsibilities in Tackling Direct-to-Consumer Marketing of Unproven Stem Cell Treatments

Zubin Master, W. Fu, D. Paciulli, D. Sipp

Research output: Contribution to journalArticle

2 Scopus citations

Abstract

The direct-to-consumer marketing of unproven stem cell interventions (SCIs) is a serious public health concern. Regulations and education have had modest impact, indicating that different actors must play a role to stop this unfettered market. We consider the role of the biotech industry in tackling unproven SCIs. Grounded in the concept of corporate social responsibility, we argue that biotech companies should screen consumers to ensure that products and services are being used appropriately and educate employees about unproven SCIs.

Original languageEnglish (US)
Pages (from-to)177-179
Number of pages3
JournalClinical Pharmacology and Therapeutics
Volume102
Issue number2
DOIs
StatePublished - Aug 1 2017

ASJC Scopus subject areas

  • Pharmacology
  • Pharmacology (medical)

Fingerprint Dive into the research topics of 'Industry Responsibilities in Tackling Direct-to-Consumer Marketing of Unproven Stem Cell Treatments'. Together they form a unique fingerprint.

  • Cite this